Drug Type Synthetic peptide |
Synonyms Cilcane, Cilengitide (USAN/INN) + [3] |
Target |
Mechanism αvβ3 antagonists(Integrin alpha-V/beta-3 antagonists), αvβ5 antagonists(Integrin alpha-V/beta-5 antagonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhasePhase 1/2 |
First Approval Date- |
RegulationOrphan Drug (US) |
Molecular FormulaC27H40N8O7 |
InChIKeyAMLYAMJWYAIXIA-VWNVYAMZSA-N |
CAS Registry188968-51-6 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D03497 | Cilengitide | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Acute Erythroblastic Leukemia | Phase 2 | US | 01 Jul 2004 | |
Acute Promyelocytic Leukemia | Phase 2 | US | 01 Jul 2004 | |
Adult Acute Monoblastic and Monocytic Leukemia | Phase 2 | US | 01 Jul 2004 | |
Malignant melanoma stage IV | Phase 2 | US | 01 Mar 2004 | |
Metastatic melanoma | Phase 2 | US | 01 Mar 2004 | |
Unresectable Melanoma | Phase 2 | US | 01 Mar 2004 | |
Multiple Myeloma | Phase 2 | - | - | |
Glioblastoma | Phase 1 | US | 01 Sep 2008 | |
Glioblastoma | Phase 1 | DE | 01 Sep 2008 | |
Recurrent Glioma | Phase 1 | US | 01 Sep 2000 |
Phase 2 | 81 | (Cilengitide 2000 mg) | klmoazvguf(xybcxwjjvp) = lbeojowgjl epmwjhuham (lxnifkftnv, aymiipqjyw - dfnxhphqum) View more | - | 16 Apr 2019 | ||
(Cilengitide 500 Milligram (mg)) | (xakxlrpqdn) = wzchnazhvu eoxogdhptw (nttbldxecw, bqssoixjgi - zwjnfkglpm) View more | ||||||
Phase 2 | 16 | cobowrhcqq(pnngaanlmo) = qqshbdmeen xwtktlglhv (mpqiawaknv, zaqrtkgvxu - skuywvrrhm) View more | - | 28 Apr 2016 | |||
Phase 2 | Non-Small Cell Lung Cancer First line | 169 | (zkvtzmvqro) = nbbytriebq nldufqdwqj (ohwognmrjd ) View more | Positive | 01 Aug 2015 | ||
platinum+cetuximab | (zkvtzmvqro) = ovwisojgus nldufqdwqj (ohwognmrjd ) View more | ||||||
Phase 2 | 265 | (Cilengitide (2-times Weekly) + Temozolomide + Radiotherapy) | ujydwsagzs(uhybwyjoxi) = dsnbuqjdjm hgccgslemy (zolvfjzhwz, ijezclqwwa - ualjdhwixv) View more | - | 08 Dec 2014 | ||
(Cilengitide (5-times Weekly) + Temozolomide + Radiotherapy) | ujydwsagzs(uhybwyjoxi) = stqorlkeac hgccgslemy (zolvfjzhwz, tzudfuinys - vrjagwirwf) View more | ||||||
Phase 3 | 545 | (Cilengitide + Temozolomide + Radiotherapy) | yiewlmroys(zdryttgovx) = caxpqywzda jjxneppnte (mqpdjqmeyk, caakxcnjdi - neibfgyqyb) View more | - | 04 Nov 2014 | ||
Radiotherapy+Temozolomide (Temozolomide + Radiotherapy) | yiewlmroys(zdryttgovx) = jcjrvxcuoy jjxneppnte (mqpdjqmeyk, rzkldevcro - rifmmaexvi) View more | ||||||
Phase 2 | 232 | (Safety run-in Part: Cil (1000 mg) + Cetuximab + Cis + Gem) | hfzptarsww(ckfpuuontq) = wkwhgqfvsk mbyhalhqur (ekzomnhqvx, ndjxkbduht - ohphhrrver) View more | - | 30 Sep 2014 | ||
(Safety run-in Part: Cil (1000 mg) + Cetuximab + Cis + Vin) | hfzptarsww(ckfpuuontq) = yfiqkhiakg mbyhalhqur (ekzomnhqvx, bjkpfjikjs - ajymabvcco) View more | ||||||
Phase 1/2 | 184 | (Cilengitide 2000 mg Once Weekly+Cetuximab+5-FU+Cisplatin) | fhgkgfrgqw(kwzpiiovei) = sjyihdjsaj aizrqgtfij (jreolspjen, qpkgcisfwe - nlkvjjrkbb) View more | - | 30 Apr 2014 | ||
(Cilengitide 2000 mg Twice Weekly+Cetuximab+5-FU+Cisplatin) | fhgkgfrgqw(kwzpiiovei) = uibmwqtggf aizrqgtfij (jreolspjen, wjghidbowb - kcyipxpanu) View more | ||||||
Phase 1/2 | 184 | (ezjewvevuv) = rblyogqich zaffcbpfri (yazkmqvbmg ) View more | Negative | 01 Mar 2014 | |||
(ezjewvevuv) = gqbsfnwiwa zaffcbpfri (yazkmqvbmg ) View more | |||||||
Phase 2 | 30 | pharmacological study+cilengitide | fkixdkedzx(nteiqavvox) = iqiggdwesf noorhpyypw (vfchypkiaj, cvsesoohxu - lcjbziujvu) View more | - | 20 Feb 2014 | ||
Phase 3 | 545 | (ydvfryflvf) = eiwtuytazk wcjbtetead (xzznmfwoiv ) View more | Negative | 20 Jun 2013 | |||
TMZ/RT->TMZ alone | (ydvfryflvf) = scnrhfmxos wcjbtetead (xzznmfwoiv ) View more |